Literature DB >> 30094613

A cross-sectional study of the reporting quality of pilot or feasibility trials in high-impact anesthesia journals.

Harsha Shanthanna1,2, Alka Kaushal3,4, Lawrence Mbuagbaw3,5, Rachel Couban4, Jason Busse3,4, Lehana Thabane6,3,5.   

Abstract

PURPOSE: Pilot trials inform the design and conduct of larger scale trials. Using the Consolidated Standards of Reporting Trials (CONSORT) pilot extension guidelines, we assessed reporting quality in five high-impact anesthesia journals and explored factors associated with reporting quality.
METHODS: The five highest-impact anesthesia journals were screened for randomized-controlled trials published as pilot or feasibility trials between 2006 and 2016. A pair of reviewers independently screened citations, extracted data, and assessed reporting quality using the CONSORT pilot trial extension checklists for abstracts and full texts. We reported the percentage adherence for each item, along with the median [interquartile range (IQR)] or mean (standard deviation [SD]) for all items. The factors considered to influence reporting were: 1) trial registration, 2) industry funding, 3) trial identification as a pilot or feasibility in the title or abstract, 4) primary objective as "feasibility", and 5) the specific journal. The association was estimated using generalized estimating equations and reported as incidence rate ratios with 99% confidence intervals.
RESULTS: Of 364 citations, 58 articles were eligible. The median [IQR] number of CONSORT abstract items reported was 5 [4-7], and the mean (SD) number of full text items reported was 13 (5). Significantly poor reporting was associated with "not registering the trial" (both abstracts and full texts), "trial not identified as a pilot" (abstracts), and "using clinical hypothesis as the primary objective" (full texts).
CONCLUSION: The reporting quality of pilot trials published in leading anesthesia journals is poor. Journal editorial boards can encourage improved reporting by supporting adherence to the CONSORT extension for pilot trials.

Entities:  

Mesh:

Year:  2018        PMID: 30094613     DOI: 10.1007/s12630-018-1194-z

Source DB:  PubMed          Journal:  Can J Anaesth        ISSN: 0832-610X            Impact factor:   5.063


  6 in total

1.  Mapping the nomenclature, methodology, and reporting of studies that review methods: a pilot methodological review.

Authors:  Daeria O Lawson; Alvin Leenus; Lawrence Mbuagbaw
Journal:  Pilot Feasibility Stud       Date:  2020-01-30

2.  Protocol for a systematic review of reporting standards of anaesthetic interventions in randomised controlled trials.

Authors:  Lucy Elliott; Karen Coulman; Natalie S Blencowe; Mahim Qureshi; Sethina Watson; Ronelle Mouton; Robert J Hinchliffe
Journal:  BMJ Open       Date:  2020-01-13       Impact factor: 2.692

3.  The reporting of progression criteria in protocols of pilot trials designed to assess the feasibility of main trials is insufficient: a meta-epidemiological study.

Authors:  Lawrence Mbuagbaw; Sarah Daisy Kosa; Daeria O Lawson; Rosa Stalteri; Oluwatobi R Olaiya; Ahlam Alotaibi; Lehana Thabane
Journal:  Pilot Feasibility Stud       Date:  2019-11-03

4.  Completeness of reporting of quality improvement studies in neonatology is inadequate: a systematic literature survey.

Authors:  Catherine Hu; Jie Yi Wang; Zoe El Helou; Muhammad Taaha Hassan; Zheng Jing Hu; Gerhard Fusch; Lawrence Mbuagbaw; Salhab El Helou; Lehana Thabane
Journal:  BMJ Open Qual       Date:  2021-06

5.  Reporting quality and spin in abstracts of randomized clinical trials of periodontal therapy and cardiovascular disease outcomes.

Authors:  Murad Shaqman; Khadijeh Al-Abedalla; Julie Wagner; Helen Swede; John Cart Gunsolley; Effie Ioannidou
Journal:  PLoS One       Date:  2020-04-17       Impact factor: 3.240

Review 6.  A tutorial on methodological studies: the what, when, how and why.

Authors:  Lawrence Mbuagbaw; Daeria O Lawson; Livia Puljak; David B Allison; Lehana Thabane
Journal:  BMC Med Res Methodol       Date:  2020-09-07       Impact factor: 4.615

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.